The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 29, 2016
Filed:
Dec. 01, 2011
Soldano Ferrone, Boston, MA (US);
Xinhui Wang, Boston, MA (US);
Elvira Favoino, Casamassima Bari, IT;
Ling Yu, Pittsburgh, PA (US);
Yangyang Wang, Pittsburgh, PA (US);
Soldano Ferrone, Boston, MA (US);
Xinhui Wang, Boston, MA (US);
Elvira Favoino, Casamassima Bari, IT;
Ling Yu, Pittsburgh, PA (US);
Yangyang Wang, Pittsburgh, PA (US);
University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US);
Abstract
Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds high molecular weight melanoma associated antigen (HMW-MAA), also known as CSPG4; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.